Markham, Ontario, Canada (PRWEB) April 6, 2006
The Gibson Group is pleased to announce the launch of interceptCS, an innovative device that completely revolutionizes the management of cold sores (herpes simplex -1). In contrast to other available therapies such as topical or oral antiviral medications, interceptCS doesn’t ‘treat’ cold sores – it prevents them before they start.
Grant Gibson, President of the Gibson Group states, “in all our years in healthcare marketing we have rarely seen a product that has an “approved” prevention claim. interceptCS will revolutionize this category. This will be a significant breakthrough for the 5 to 10 million Canadians who suffer from recurrent cold sore outbreaks. Now, many of these patients can look forward to a lifetime without cold sores.”
interceptCS is a unique personal medical device that utilizes precisely targeted Thermal Defence Technology to stimulate the body’s cellular immune response. Patients use the interceptCS Cold Sore Prevention System as soon as they feel the characteristic tingling sensation that indicates a cold sore is about to emerge. interceptCS is quick, painless and convenient to use – just three 30-second treatments safely and effectively prevents the cold sore from developing.
The launch of interceptCS will consist of a national radio campaign, web advertising, and a Pharmacist education program.
The interceptCS Cold Sore Prevention system is available exclusively through Shoppers Drug Mart/Pharmaprix.
With interceptCS, Feel the tingle. Stop your cold sore.™ For further information on interceptCS, call Allison Boyd of The Gibson Group at 905-475-0371 or visit: http://www.interceptCS.com.
For further information on The Gibson Group please visit our web site at http://www.thegibsongroup.ca or call Allison Boyd at 905-475-0371